ALLMedicine™ Triple-negative Breast Cancer Center

May 4th, 2021 - Effect of Adjuvant Metronomic Capecitabine on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer-Reply.|2021|Bi XW,Hua X,Yuan ZY,|

May 4th, 2021 - Effect of Adjuvant Metronomic Capecitabine on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer.|2021|Du F,Yuan P,|

May 2nd, 2021 - Capsanthin is a naturally occurring red pepper carotenoid with possible antitumor activity, but its antitumor mechanisms have yet to be delineated. We tested the anti-proliferative activity of capsanthin with human triple-negative breast cancer (T...

May 2nd, 2021 - Patients with triple-negative breast cancer (TNBC) face a major challenge of the poor prognosis, and N6-methyladenosine-(m6A) mediated regulation in cancer has been proposed. Therefore, this study aimed to explore the prognostic roles of m6A-relat...

May 2nd, 2021 - We identified a rare missense germline mutation in BARD1 (c.403G>A or p.Asp135Asn) as pathogenic using integrated genomics and transcriptomics profiling of germline and tumor samples from an early-onset triple-negative breast cancer patient who la...

May 31st, 2020

May 30th, 2020 - For patients with BRCA-like triple-negative breast cancer (TNBC), adding veliparib to cisplatin chemotherapy may extend survival, based on results from the phase 3 SWOG S1416 trial.

May 29th, 2020 - A year of maintenance therapy with metronomic capecitabine after standard treatment extended DFS among women with operable triple-negative breast cancer, according to study results presented at ASCO20 Virtual Scientific Program.

May 29th, 2020 - The proton pump inhibitor (PPI) omeprazole may be a useful addition to treatment for triple-negative breast cancer, as it boosted the expected rate of tumor disappearance among women with early-stage disease, according to the results of a phase 2 ...

May 29th, 2020 - For patients with triple-negative breast cancer (TNBC), 1 year of capecitabine treatment after standard therapy may lead to significantly better disease-free survival (DFS), but not overall survival (OS), according to results of a phase 3 trial.

May 4th, 2021 - Effect of Adjuvant Metronomic Capecitabine on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer-Reply.|2021|Bi XW,Hua X,Yuan ZY,|

May 4th, 2021 - Effect of Adjuvant Metronomic Capecitabine on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer.|2021|Du F,Yuan P,|

May 2nd, 2021 - Capsanthin is a naturally occurring red pepper carotenoid with possible antitumor activity, but its antitumor mechanisms have yet to be delineated. We tested the anti-proliferative activity of capsanthin with human triple-negative breast cancer (T...

May 2nd, 2021 - Patients with triple-negative breast cancer (TNBC) face a major challenge of the poor prognosis, and N6-methyladenosine-(m6A) mediated regulation in cancer has been proposed. Therefore, this study aimed to explore the prognostic roles of m6A-relat...

May 2nd, 2021 - We identified a rare missense germline mutation in BARD1 (c.403G>A or p.Asp135Asn) as pathogenic using integrated genomics and transcriptomics profiling of germline and tumor samples from an early-onset triple-negative breast cancer patient who la...

Apr 21st, 2021 - NEW YORK (Reuters Health) - Immunomedics' antibody-drug conjugate sacituzumab govitecan can cut the risk of disease progression or death by 59% and nearly double median overall survival among women with metastatic triple-negative breast cancer, ac...

Mar 4th, 2021 - For patients with triple-negative breast cancer (TNBC), neoadjuvant carboplatin plus docetaxel yields the same pathologic complete response and survival rates as a standard anthracycline-based neoadjuvant regimen ― carboplatin and paclitaxel follo...

Feb 2nd, 2021 - Researchers say women with type 2 diabetes treated with metformin had a reduced rate of the most common type of breast cancer, estrogen receptor (ER)-positive tumors, during a median follow-up of nearly 9 years in a prospective study of more than ...

Feb 2nd, 2021 - This transcript has been edited for clarity. I'm excited to update you on some of the progress that's been made about sacituzumab govitecan over the past couple of weeks. So, sacituzumab govitecan is an antibody-drug conjugate. The antibody part i...

Dec 15th, 2020 - Adding the oral AKT inhibitor ipatasertib to paclitaxel does not improve progression-free survival (PFS) for women with PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC), suggests the phase ...